Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Conditions: Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration Intervention: Drug: LOXO-292 Sponsors: Loxo Oncology, Inc.; Eli Lilly and Company Available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials